Sagna Tani, Ouedraogo Paul, Traore Lassina, Obiri-Yeboah Dorcas, Yonli Albert, Tapsoba Aristide, Tovo Frida, Sorgho Abel, Zongo Laetitia, Nikiema Ouégo, Ilboudo Dénise, Belemgnegre Marius, Nadembega Christelle W, Ouermi Djeneba, Djigma Florencia W, Zohoncon Théodora M, Poaty Henriette, Colizzi Vittorio, Simpore Jacques
Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, Burkina Faso.
J Public Health Afr. 2022 May 25;13(1):1778. doi: 10.4081/jphia.2022.1778. eCollection 2022 May 24.
The severe acute respiratory syndrome due to the new coronavirus (SARS-CoV-2), responsible for coronavirus disease (COVID-19), has severely tested the global health response capacity, with predictions of a fatality for developing countries. To evaluate the prevalence of anti-SARS-CoV- 2 antibodies in People Living with HIV (PLHIV) with no COVID-19 symptoms in Burkina Faso. Seroprevalence was estimated by performing a qualitative screening test for SARS-CoV-2-specific immunoglobulins. The STANDARD Q COVID-19 IgM/IgG Combo Test kit from SD BIOSENSOR was used. Parameters like HIV plasma viral load, CD4 T cell count and C-Reactive Protein (CRP) expression were estimated. This study enrolled a total of 200 PLHIV aged 4-87 years who are asymptomatic for COVID-19. There were 36 (18%) positive for SARS-CoV-2 IgM and/or IgG of which three (1.50%) were positive for SARS-CoV-2 IgM and 33 (16.50%) for IgG. Among participants diagnosed as IgM positive, 66.67% (2/3) had the highest HIV viral loads with the lowest CD4 T cell counts (p<0.0001). The expression of CRP was relatively higher in COVID-19 IgG positive individuals (7.95±12.5 mg/L) than negative individuals (6.26±6.92 mg/L; p=0.37). The rate of IgG and IgM SARS-CoV-2 immunoglobulin carriage (18%), accompanied by a relatively high CRP levels, was revealed in this study among PLHIV. This serologic evidence and mild inflammation suggest that Burkina Faso escaped the worst, not necessarily because there were not many SARS-CoV-2 infections in its population, but because factors including genetic and environmental, might have resulted in many asymptomatic carriers.
由新型冠状病毒（SARS-CoV-2）引起的严重急性呼吸综合征，即冠状病毒病（COVID-19），对全球卫生应对能力进行了严峻考验，预计发展中国家会出现死亡病例。为评估布基纳法索无COVID-19症状的艾滋病毒感染者（PLHIV）中抗SARS-CoV-2抗体的流行情况。通过对SARS-CoV-2特异性免疫球蛋白进行定性筛查试验来估计血清阳性率。使用了SD BIOSENSOR的标准Q COVID-19 IgM/IgG组合检测试剂盒。对HIV血浆病毒载量、CD4 T细胞计数和C反应蛋白（CRP）表达等参数进行了评估。本研究共纳入了200名年龄在4至87岁、无COVID-19症状的PLHIV。SARS-CoV-2 IgM和/或IgG检测呈阳性的有36例（18%），其中SARS-CoV-2 IgM阳性3例（1.50%），IgG阳性33例（16.50%）。在诊断为IgM阳性的参与者中，66.67%（2/3）的HIV病毒载量最高，CD4 T细胞计数最低（p<0.0001）。COVID-19 IgG阳性个体的CRP表达（7.95±12.5 mg/L）相对高于阴性个体（6.26±6.92 mg/L；p=0.37）。本研究在PLHIV中发现了SARS-CoV-2免疫球蛋白IgG和IgM携带率（18%），并伴有相对较高的CRP水平。这一血清学证据和轻度炎症表明，布基纳法索躲过了最糟糕的情况，不一定是因为其人口中SARS-CoV-2感染不多，而是因为包括遗传和环境等因素可能导致了许多无症状携带者。
